Home » Stocks » ENTA

Enanta Pharmaceuticals, Inc. (ENTA)

Stock Price: $48.50 USD -2.50 (-4.90%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 989.84M
Revenue (ttm) 101.65M
Net Income (ttm) -57.94M
Shares Out 20.09M
EPS (ttm) -2.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $48.50
Previous Close $51.00
Change ($) -2.50
Change (%) -4.90%
Day's Open 51.29
Day's Range 48.50 - 52.06
Day's Volume 140,169
52-Week Range 40.32 - 58.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic hepatitis B virus (HBV) patients already being ...

21 hours ago - Benzinga

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -15.96% and -21.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Conference Call Today at 4:30 p.m. ET

1 day ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic HBV Patients on NUC Treatment

1 day ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2021

1 week ago - Business Wire

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

2 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference

2 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 50.00% and 19.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 163.08% year over year to ($0.41), ...

2 months ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Conference Call Today at 4:30 p.m. ET

2 months ago - Business Wire

Enanta Pharmaceuticals (NASDAQ:ENTA) unveils its next round of earnings this Monday, February 08. Get prepared with Benzinga's ultimate preview for Enanta Pharmaceuticals's Q1 earnings.

3 months ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter

3 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

3 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Provide Updates on its R&D Programs and Outlook for 2021 at the 39th Annual J.P. Morgan Healthcare Conference

3 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology

4 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

4 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development

4 months ago - Business Wire

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q4 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 40.22% and -7.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 431.82% over the past year to ($1.4...

5 months ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at Upcoming Conferences

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on November 23 to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

5 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference

7 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for NASH

7 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in Upcoming September Conferences

8 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress

8 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Data Presentations at European Association for the Study of the Liver’s (EASL) Digital International Liver Congress

8 months ago - Business Wire

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 2.74% and -37.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat after the company reported Q3 results.

9 months ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m.

9 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference 2020

9 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Host Conference Call on August 4 at 4:30 p.m.

9 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 58.90% and -9.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.

Other stocks mentioned: GILD, LLY, MRNA, REGN, RHHBY, SNY
1 year ago - Zacks Investment Research

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

Other stocks mentioned: AYTU, CANF, LJPC, LLY, OPK, RHHBY
1 year ago - Benzinga

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2020 Results Conference Call February 6, 2020 4:30 PM ET

1 year ago - Seeking Alpha

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 10.17% and -11.37%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

The small drugmaker depends on royalties from HCV drug Mavyret. And those sales aren't as strong as they used to be.

Other stocks mentioned: ABBV
1 year ago - The Motley Fool

Enanta Pharmaceuticals' (ENTA) CEO Jay Luly on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -22.81% and -8.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.

1 year ago - Zacks Investment Research

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Labo... [Read more...]

Industry
Biotechnology
IPO Date
Mar 21, 2013
CEO
Jay Luly
Employees
141
Stock Exchange
NASDAQ
Ticker Symbol
ENTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ENTA stock is "Hold." The 12-month stock price forecast is 67.86, which is an increase of 39.92% from the latest price.

Price Target
$67.86
(39.92% upside)
Analyst Consensus: Hold